Stents capable of controllably releasing histone deacetylase inhibitors
A stent device is provided. The stent device includes a stent body and one or more HDAC inhibitor depot(s) provided on or in the stent body, the depot(s) capable of controllably releasing HDAC inhibitor(s). Methods of using the stents in treating and/or preventing restenosis are provided. A delivery system including the stent device and a methods of using the delivery system in treating and/or preventing restenosis are also provided. Kits comprising stents are provided.
1 . A stent device comprising a stent body and one or more HDAC inhibitor depots, said one or more HDAC inhibitor depots being located on or in said stent body, said one or more HDAC inhibitor depots comprising one or more HDAC inhibitors, and said one or more HDAC inhibitor depots being capable of controllably releasing at least one of said one or more HDAC inhibitors.
2 . The stent device of claim 1 , wherein at least one of said one or more HDAC inhibitor depots further comprises one or more additional pharmaceutical agents, at least one of said one or more additional pharmaceutical agents selected from the group consisting of an anticoagulant agent, an antiproliferative agent, an antimigratory agent, an antimetabolic agent, an anti-inflammatory agent and an immunosuppressive agent.
3 . The stent device of claim 2 , wherein at least one of said one or more HDAC inhibitor depots is capable of controllably releasing at least one of said one or more additional pharmaceutical agents.
4 . The stent device of claim 1 , further comprising one or more additional pharmaceutical agent depots, said one or more additional pharmaceutical agent depots being located on or in said stent body, said one or more additional pharmaceutical agent depots comprising one or more additional pharmaceutical agents, and at least one of said one or more additional pharmaceutical agent depots being capable of controllably releasing at least one of said one or more additional pharmaceutical agents.
5 . The stent device of claim 4 , wherein at least one of said one or more additional pharmaceutical agents is selected from the group consisting of an anticoagulant agent, an antiproliferative agent, an antimigratory agent, an antimetabolic agent, an anti-inflammatory agent and an immunosuppressive agent.
6 . The stent device of claim 1 , wherein at least one of said one or more HDAC inhibitor depots comprises one or more biocompatible polymers loaded with at least one of said one or more HDAC inhibitors.
7 . (Cancelled)
8 . (Cancelled)
9 . (Cancelled)
10 . (Cancelled)
11 . (Cancelled)
12 . The stent device of claim 1 , wherein at least one of said one or more HDAC inhibitors is a hydroxamic acid.
13 . The stent device of claim 12 , wherein said hydroxamic acid is selected from the group consisting of TSA, SAHA, oxamflatin, CBHA, CHAP1, CHAP31, SBHA, pyroxamide, and scriptaid.
14 . The stent device of claim 13 , wherein said hydroxamic acid is TSA.
15 . The stent device of claim 1 , wherein at least one of said one or more HDAC inhibitors is selected from the group consisting of a short-chain fatty acid, a cyclic tetrapeptide, a benzamide derivative, a valproic acid derivative, a carbamic acid derivative, an allyl sulfide-containing compound, an oxyalkylene ester derivative, and an oxyalkylene phosphate derivative.
16 . (Cancelled)
17 . (Cancelled)
18 . (Cancelled)
19 . The stent device of claim 1 , wherein said stent body comprises a polymer.
20 . (Cancelled)
21 . (Cancelled)
22 . (Cancelled)
23 . A stent delivery system comprising:
(a) a delivery catheter; and
(b) a stent device comprising a stent body and one or more HDAC inhibitor depots, said one or more HDAC inhibitor depots being located on or in said stent body, said one or more HDAC inhibitor depots comprising one or more HDAC inhibitors, and said one or more HDAC inhibitor depots being capable of controllably releasing at least one of said one or more HDAC inhibitors,
wherein said stent device is capable of being detachably attached to said delivery catheter.
24 . The stent delivery system of claim 23 , wherein at least one of said one or more HDAC inhibitor depots further comprises one or more additional pharmaceutical agents, at least one of said one or more additional pharmaceutical agents selected from the group consisting of an anticoagulant agent, an antiproliferative agent, an antimigratory agent, an antimetabolic agent, an anti-inflammatory agent and an immunosuppressive agent.
25 . The stent delivery system of claim 24 , wherein at least one of said one or more HDAC inhibitor depots is capable of controllably releasing at least one of said one or more additional pharmaceutical agents.
26 . The stent delivery system of claim 23 , wherein said stent device further comprises one or more additional pharmaceutical agent depots, said one or more additional pharmaceutical agent depots being located on or in said stent body, said one or more additional pharmaceutical agent depots comprising one or more additional pharmaceutical agents, and at least one of said one or more additional pharmaceutical agent depots being capable of controllably releasing at least one of said one or more additional pharmaceutical agents.
27 . The stent delivery system of claim 26 , wherein at least one of said one or more additional pharmaceutical agents is selected from the group consisting of an anticoagulant agent, an antiproliferative agent, an antimigratory agent, an antimetabolic agent, an anti-inflammatory agent and an immunosuppressive agent.
28 . The stent delivery system of claim 23 , wherein at least one of said one or more HDAC inhibitor depots comprises one or more biocompatible polymers loaded with at least one of said one or more HDAC inhibitors.
29 . The stent delivery system of claim 28 , wherein at least one of said one or more biocompatible polymers is a biostable polymer.
30 . The stent delivery system of claim 28 , wherein at least one of said one or more biocompatible polymers is a biodegradable polymer.
31 . The stent delivery system of claim 26 , wherein at least one of said one or more additional pharmaceutical agent depots comprises one or more biocompatible polymers loaded with at least one of said one or more additional pharmaceutical agents.
32 . (Cancelled)
33 . (Cancelled)
34 . (Cancelled)
35 . (Cancelled)
36 . (Cancelled)
37 . (Cancelled)
38 . (Cancelled)
39 . (Cancelled)
40 . (Cancelled)
41 . (Cancelled)
42 . (Cancelled)
43 . (Cancelled)
44 . (Cancelled)
45 . (Cancelled)
46 . (Cancelled)
47 . (Cancelled)
48 . (Cancelled)
49 . (Cancelled)
50 . (Cancelled)
51 . (Cancelled)
52 . (Cancelled)
53 . (Cancelled)
54 . (Cancelled)
55 . (Cancelled)
56 . (Cancelled)
57 . (Cancelled)
58 . (Cancelled)
59 . (Cancelled)
60 . (Cancelled)
61 . (Cancelled)
62 . (Cancelled)
63 . (Cancelled)
64 . (Cancelled)
65 . (Cancelled)
66 . (Cancelled)
67 . (Cancelled)